Revolutionary CRISPR Therapy Approved for Sickle Cell Treatment in the U.S
In a landmark decision, the U.S. Food and Drug Administration has approved the first-ever CRISPR-based therapy, Casgevy, to treat sickle cell disease in patients aged 12 years and older. This pioneering treatment offers a new ray of hope for those suffering from severe forms of this painful blood disorder. Developed by Vertex Pharmaceuticals in collaboration…
